The ENTRUST-AF PCI trial investigated the combination of the factor Xa-inhibitor edoxaban (in the approved dose of 1*60 mg/day or 1*30 mg/day in case of dose reduction criteria as in ENGAGE [14]) with mostly clopidogrel following PCI in AF. The gene discussed is F10; the disease is atrial fibrillation.